-

Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has been named by U.S. News & World Report as one of the best companies to work for in healthcare.

Natera was ranked among 349 companies across 20 fields of work on factors contributing to job seekers’ decision-making when choosing a workplace that best meets their needs in their industries of interest. In healthcare specifically, Natera earned a spot on the industry list alongside companies across different elements of healthcare operations and services, including biotechnology, life sciences, pharmaceuticals, and hospital operations.

“At Natera, we are committed to fostering a positive workplace environment where employees can learn from one another, further develop in their careers, and continue to thrive – all while contributing to our very important mission,” said Steve Chapman, chief executive officer of Natera. “Natera is a great place to work because of our extremely talented employees, and we are proud to earn a spot on this list alongside so many esteemed companies across different dimensions of healthcare.”

This new recognition by U.S. News expands on the general 2023-2024 U.S. News Best Companies to Work For list by looking at how companies measure up to the expectations of their employees within their respective industries. The rankings take into account quality of pay, work-life balance, and opportunities for professional development and advancement by industry.

To calculate the U.S. News Best Companies to Work For by Industry lists, U.S. News only considered companies that were a part of the Russell 3000 index as of June 2023 and scored in the top 20% of their industry. Additionally, U.S. News required each company to have a minimum of 75 Glassdoor reviews written between 2020-2022 and grouped companies according to the Industry Classification Benchmark (ICB) used by the FTSE Russell.

To learn more about career opportunities at Natera and the core values that define company culture, please visit: www.natera.com/company/careers/.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Industry:

Natera, Inc.

NASDAQ:NTRA
Release Versions
English

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

More News From Natera, Inc.

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 13, 2026 at 4:30 p.m. PT (7:30 p.m. ET). Members of management will deliver a presentation and host a Q&A with the investment community at the conference. A live webcast may be accessed through the investor relations section of the Natera websit...

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year. CALGB (Alliance)/SWOG 80702 assessed the predictive value of postoperative...

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Quantum Leap Healthcare Collaborative, today announced the publication of new findings from the I-SPY 2 trial in Nature Communications. The study examined how Signatera can refine risk assessment in patients with early-stage breast cancer whose tumors resist neoadjuvant therapy (NAT). These cancers often leave behind substantial residual disease and carry a higher...
Back to Newsroom